Dergiler / Klinik Psikofarmakoloji Bülteni / 2012 / Cilt: 22 - Sayı: 1

Individual differences in the pharmacokinetics of clozapine in healthy Chinese adults

Sayfa
17–22
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Psychiatrists and pharmacists may need to have more patience and pay more attention to high variability in response to clozapine among schizophrenic patients with differences in weight, age, liver function, renal function, and pharmacogenetics.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction: Differences in response to clozapine among patients have received considerable attention.
📊
Temel Bulgular & Veri:Methods: A total of 18 volunteers who received 12.5mg of clozapine participated in the study.
💡
Sonuç & Katkı:Psychiatrists and pharmacists may need to have more patience and pay more attention to high variability in response to clozapine among schizophrenic patients with differences in weight, age, liver function, renal function, and pharmacogenetics.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Introduction: Differences in response to clozapine among patients have received considerable attention. Individual pharmacokinetic differences are a major reason. Objective: The aim of this study was to investigate the pharmacokinetic variability in the blood levels ofclozapine among young, healthy, Chinese male volunteers. Methods: A total of 18 volunteers who received 12.5mg of clozapine participated in the study. Blood samples were measured by using High-Performance Liquid Chromatography-Electrospray ionization tandem mass spectrometry (LC-MS/ MS). The major pharmacokinetic parameters were calculated from the plasma concentration-time curve and individual variability was assessed. Results: The findings indicated that the AUC0-48h, Cmax and t1/2 varied 2.9, 2.6, and 2.0 fold, respectively among the individuals even with similar physiological status. Conclusions: Individual differences were obvious among healthy volunteers and greater differences could have been observed if more subjects had been included in the study. Psychiatrists and pharmacists may need to have more patience and pay more attention to high variability in response to clozapine among schizophrenic patients with differences in weight, age, liver function, renal function, and pharmacogenetics.

🔖

Bu Makaleye Atıf Yap

LİU, Y., Lİ, H., YAN, M. (2022). Individual differences in the pharmacokinetics of clozapine in healthy Chinese adults. Klinik Psikofarmakoloji Bülteni, Cilt: 22 - Sayı: 1, 17–22. https://ajindex.com/articles/574126

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Agelink MW, Sayar K, Klieser E. Usefulness of heart rate variability (HRV) for monitoring clozapine plasma levels. Pharmacopsychiatry 2003;36(4):166-7
  2. Eschweiler GW, Bartels M, Langle G, Wild B, Gaertner I, Nickola M. Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine. Pharmacopsychiatry 2002;35(3):96-100
  3. Rajji TK, Uchida H, Ismail Z, Ng W, Mamo DC, Remington G, et al. Clozapine and global cognition in schizophrenia. J Clin Psychopharmacol 2010;30(4):431-6
  4. McKean A, Vella-Brincat J, Begg E. Prescribing and monitoring clozapine in Christchurch. Australas Psychiatry 2008;16(4):263-7
  5. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008;84(3):417-23
  6. Sternieri E, Pinetti D, Coccia CP, Leone S, Bertolini A, Ferrari A. Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. J Headache Pain 2005;6(4):319-21
  7. Lee ST, Ryu S, Nam HJ, Lee SY, Hong KS. Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients. Int Clin Psychopharmacol 2009;24(3):139- 44
  8. Qiu XW, Fu PX, Wang CY, Liu M, Zhou TY, Lu W. Population pharmacokinetics research of clozapine in Chinese schizophrenic patients. Yao Xue Xue Bao 2009;44(7):785-92
  9. Raedler TJ, Hinkelmann K, Wiedemann K. Variability of the in vivo metabolism of clozapine. Clin Neuropharmacol 2008;31(6):347-52
  10. Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2000;49(1):59-63
  11. Tang YL, Mao P, Li FM, Li W, Chen Q, Jiang F, et al.Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol 2007;64(1): 49-56
  12. Raedler TJ, Hinkelmann K, Wiedemann K. Variability of the in vivo metabolism of clozapine. Clin Neuropharmacol 2008;31(6):347-52
  13. Balibey H, Basoglu C, Lundgren S, Babaoglu MO, Yasar U, Herken H, et al. CYP1A2*1F polymorphism decrease clinical response to clozapine in patients with schizophrenia. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2011;21(2):93-9
  14. Wohlfarth A, Toepfner N, Hermanns-Clausen M, Auwarter V. Sensitive quantification of clozapine and its main metabolites norclozapine and clozapine-N-oxide in s